Short Interest in PainReform Ltd. (NASDAQ:PRFX) Drops By 13.3%

PainReform Ltd. (NASDAQ:PRFX) was the target of a large decrease in short interest in the month of March. As of March 13th, there was short interest totaling 68,090 shares, a decrease of 13.3% from the February 26th total of 78,499 shares. Approximately 25.8% of the shares of the company are sold short. Based on an average trading volume of 28,070 shares, the short-interest ratio is presently 2.4 days.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of PainReform in a research note on Thursday, January 22nd. One research analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the stock currently has an average rating of “Sell”.

PainReform Price Performance

PRFX stock opened at $2.03 on Wednesday. PainReform has a 1 year low of $1.80 and a 1 year high of $17.95. The company has a market cap of $810,000.00, a P/E ratio of 0.00 and a beta of 0.55. The stock’s fifty day moving average price is $2.97 and its 200-day moving average price is $4.51.

PainReform (NASDAQ:PRFX) last posted its quarterly earnings data on Thursday, March 26th. The company reported ($0.98) EPS for the quarter.

About PainReform

PainReform Ltd., a clinical stage specialty pharmaceutical company, focuses on the reformulation of established therapeutics and provides an extended period of post-surgical pain relief in Israel. It develops PRF-110, a viscous clear oil-based solution that is instilled directly into the surgical wound to provide localized and extended post-operative analgesia, as well as in Phase 3 clinical trial for pain treatment of patients undergoing bunionectomy and second trial for pain treatment of hernia repair operations.